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Human papillomaviruses (HPVs) are small, circular, double-stranded DNA viruses that are linked to the malignant transformation of epithelia of various human sites ([@B1]). Currently, more than 200 HPV genotypes have been fully characterized, including five genera of papillomaviruses---alpha, beta, gamma, mu, and nu ([@B2], [@B3]). An HPV genome is considered a novel type if its L1 genomic region shares less than 90% similarity with the closest known HPV genotype ([@B3], [@B4]). Here, we describe the discovery of a novel gammapapillomavirus isolated from a cervical swab specimen (stored in PreservCyt liquid) taken from a 24-year-old woman participating in a vaccine efficacy study and vaccinated with two doses of quadrivalent HPV vaccine. The cytological result was negative for intraepithelial lesion and malignancy.

Following DNA extraction using the Qiagen DNA minikit (Qiagen, Germany), DNA was enriched using rolling circle amplification (RCA) according to the manufacturer's instructions (illustra TempliPhi, GE Healthcare, USA) ([@B5]). A library was prepared using the Nextera XT kit (Illumina, Inc., USA), followed by next-generation sequencing on the Illumina MiniSeq platform (Illumina, Inc.). Of a total of 1,226,786 reads, 40,737 (3.3%) were mapped using BBMap within Geneious version 11 ([@B6]) to 286 known HPV genotypes downloaded from the Papillomavirus Episteme database ([@B2]), which was accessed on 24 November 2017. Reads mapped to 11 different genotypes (51, 58, 66, 67, 73, 87, 89, 90, 91, 101, and MF588697) using a minimal threshold of 10 reads. *De novo* assembly using SPAdes version 3.10.0 in Geneious yielded 6 completely known HPV genotypes (51, 66, 67, 87, 89, and MF588697) and 1 novel genotype (16031680A). Long-range PCR was performed with the RCA product using TaKaRa-LA *Taq* DNA polymerase (TaKaRa Bio, Inc.), which was cloned using the TOPO XL PCR cloning kit (Invitrogen, USA) and sequenced. The clone was submitted to the HPV reference center in Stockholm.

The L1 open reading frame (ORF) of HPV isolate 16031680A showed 77% nucleotide identity with the closest genotype, HPV101, belonging to the gamma-6 species, and analysis using BLAST showed 77% pairwise identity for the full genome. The complete genome of this novel HPV genotype consists of 7,313 nucleotides with a G+C content of 42.6%. It has four early (E1, E2, E4, and E7) and two late (L1 and L2) ORFs. The ORF coding the early protein E6 is absent, as it is for other known members of the gamma-6 species, namely, 101, 103, and 108 ([@B7][@B8][@B9]). The long control region of 735 nucleotides found between the L1 and E7 genes contains one TATA box (TATAAA) and three palindromic E2-binding sites (ACC-N~6~-GGT). One conserved zinc-binding domain was identified in the E7 protein \[CxxC(x)~29~CxxC\], and the ATP-binding site of the ATP-dependent helicase (GPPDTGKS) was identified in the carboxy-terminal region of E1 ([@B7]).

To conclude, we discovered a novel genotype of the gamma-6 papillomavirus species. Members of this species are adapted to the mucosal niche ([@B9]) and may be associated with low-grade ([@B8]) and high-grade cervical lesions ([@B7]). The clinical relevance and prevalence of gamma-6 genotypes deserves further investigation.
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The complete genome sequence for human gammapapillomavirus isolate 16031680A is available in GenBank under accession number [MG813996](https://www.ncbi.nlm.nih.gov/nuccore/MG813996).
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